S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NYSE:ARAAmerican Renal Associates Stock Price, Forecast & News

$6.20
-0.25 (-3.88 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.20
Now: $6.20
$6.60
50-Day Range
$5.80
MA: $6.37
$6.99
52-Week Range
$5.57
Now: $6.20
$13.80
Volume107,057 shs
Average Volume97,629 shs
Market Capitalization$209.18 million
P/E Ratio23.85
Dividend YieldN/A
Beta1.6
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Read More
American Renal Associates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone978-922-3080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$822.52 million
Cash Flow$1.62 per share
Book Value$2.59 per share

Profitability

Net Income$-13,790,000.00

Miscellaneous

Employees4,977
Market Cap$209.18 million
Next Earnings Date8/10/2020 (Estimated)
OptionableOptionable
$6.20
-0.25 (-3.88 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











American Renal Associates (NYSE:ARA) Frequently Asked Questions

How has American Renal Associates' stock been impacted by COVID-19 (Coronavirus)?

American Renal Associates' stock was trading at $7.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARA stock has decreased by 13.2% and is now trading at $6.20.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of American Renal Associates?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for American Renal Associates
.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for American Renal Associates
.

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) announced its earnings results on Monday, May, 11th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. The firm earned $193.18 million during the quarter, compared to analyst estimates of $201.73 million. American Renal Associates had a positive return on equity of 16.46% and a negative net margin of 2.14%.
View American Renal Associates' earnings history
.

What price target have analysts set for ARA?

3 brokers have issued 1-year target prices for American Renal Associates' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate American Renal Associates' stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for American Renal Associates
.

Has American Renal Associates been receiving favorable news coverage?

News stories about ARA stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. American Renal Associates earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about American Renal Associates
.

Are investors shorting American Renal Associates?

American Renal Associates saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 1,100,000 shares, a drop of 6.8% from the June 30th total of 1,180,000 shares. Based on an average daily volume of 99,600 shares, the days-to-cover ratio is currently 11.0 days. Approximately 3.6% of the company's shares are short sold.
View American Renal Associates' Current Options Chain
.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Akorn (AKRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), KemPharm (KMPH), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), AbbVie (ABBV), Collegium Pharmaceutical (COLL), Catalyst Pharmaceuticals (CPRX) and Fate Therapeutics (FATE).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the following people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.24%), Tsfg LLC (0.03%) and UBS Group AG (0.02%).
View institutional ownership trends for American Renal Associates
.

Which major investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for American Renal Associates
.

Which major investors are buying American Renal Associates stock?

ARA stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, and Tsfg LLC.
View insider buying and selling activity for American Renal Associates
.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $6.20.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $209.18 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. American Renal Associates employs 4,977 workers across the globe.

What is American Renal Associates' official website?

The official website for American Renal Associates is www.americanrenal.com.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.